SUBSCRIBE
SUBSCRIBE

Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS
Diverse cultures, international communication concept. Human silhouette with speech bubbles.
Regulatory
Former FDA Officials Sound Alarm: Visible Changes May Be ‘Tip of the Iceberg’
In the wake of unprecedented workforce cuts at the FDA, former Commissioner Scott Gottlieb and an unnamed former CBER director spoke to analysts about potential implications for drug review timelines and agency morale.
April 16, 2025
 · 
3 min read
 · 
Heather McKenzie
Find understanding between people. Reach your opponent. Building a bridge of understanding and reasoning. Discover common ground. Pave way for cooperation or peaceful disagreement. Resolving conflict
Mergers & acquisitions
Bluebird’s Second Suitor, Ayrmid, Fails To Produce an Offer
Despite making an unsolicited bid for gene therapy maker bluebird bio, Ayrmid failed to deliver a binding offer after weeks of due diligence. Bluebird’s board recommended that it go with Carlyle and SK Capital Partner’s original offer to take the company private for $30 million.
April 16, 2025
 · 
1 min read
 · 
Dan Samorodnitsky
Lungs health and pulmonology as a respiratory medicine conept for pulmonary science and lung cancer or respiration disease and bronchi breathing or asthma symbol in a 3D illustration style.
Clinical research
Sanofi’s $1.4B Kymab Bet Falters as Asthma Drug Stumbles in Phase II
Analysts at Leerink agreed with Sanofi that, despite falling short of statistical significance in the Phase II TIDE-Asthma trial, amlitelimab warrants further development in this indication.
April 16, 2025
 · 
2 min read
 · 
Tristan Manalac
European Union flags in front of the blurred European Parliament in Brussels, Belgium
Europe
With Tariffs Looming, EU and US Pharmas Make Demands of European Commission
Playing both sides of trade war, pharma companies are asking for certain compensations for scientific innovation and a smoother regulatory framework.
April 16, 2025
 · 
2 min read
 · 
Tristan Manalac
Pill coming out of jar forms a price increase graph. Cost of drugs on the rise. Healthcare costs and the high price of quality health care insurance concept. The cost of pills and tablets increasing. Vector illustration
Drug pricing
‘Finally, Some Good News’: Trump Signals Support for Removing IRA’s Pill Penalty
Analysts are “cautiously optimistic” about Trump’s executive order, noting that changes to the IRA drug price negotiation program will still require Congressional action before being implemented.
April 16, 2025
 · 
2 min read
 · 
Tristan Manalac
Art 3d banner collage of business people dollar roll cooperation success payment capital profit transaction money corruption.
Rare diseases
Glycomine Gets $115M Series C for Rare Disease, Aims for Phase II Launch Mid-Year
The raise will go toward trialing the company’s lead drug for phosphomannomutase-2 congenital disorder of glycosylation, a rare disease that affects the entire body and produces a wide range of symptoms.
April 16, 2025
 · 
2 min read
 · 
Dan Samorodnitsky
Podcast
Tariff Turmoil, FDA’s Future, Pfizer’s Obesity Setback and CEO Salaries Revealed
Donald Trump takes biopharma on a tariff-themed rollercoaster ride; J&J kicks off the Q1 earnings season; experts express concern about the FDA’s future; Pfizer’s obesity setback could be Viking’s gain; and BioSpace reveals the highest paid pharma CEOs.
April 16, 2025
 · 
1 min read
 · 
Heather McKenzie
Business concept illustration of businessman balancing himself with dollar coin on a rope, vector illustration
Earnings
J&J Sets Tariff Tone as Q1 Earnings Begin To Roll In
Analysts have had to throw out their assumptions for the biopharma industry’s recovery heading into the first quarter earnings period given the ongoing tariff drama.
April 16, 2025
 · 
3 min read
 · 
Annalee Armstrong
Concept of wealth. Human hand holding dollar money in pop art style. Vector illustration
Compensation
Top 6 Highest-Paid Pharma CEOs in 2024
Johnson & Johnson’s Joaquin Duato is no longer the highest paid CEO in pharma. Meanwhile, just two women make the top 10.
April 16, 2025
 · 
7 min read
 · 
Annalee Armstrong
Load More
Visit website
Email Us
IN THE PRESS
Press Releases
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
June 2, 2025
 · 
4 min read
BioMidwest
Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings
December 8, 2022
 · 
4 min read
Business
Parexel Announces Strategic Collaboration with Synexa Life Sciences and Drawbridge Health for COVID-19 Clinical Serology Testing Solution
November 2, 2020
 · 
4 min read
JOBS